drugset / Trial / NCT07680790
Study of Izalontamab Brengitecan (BMS-986507) in Combination With Osimertinib Versus Osimertinib Monotherapy or Osimertinib in Combination With Platinum-based Chemotherapy for EGFRmt Non-small Cell Lung Cancer (IZABRIGHT-Lung02)
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate izalontamab brengitecan (iza-bren) combined with osimertinib in participants with previously untreated, locally advanced or metastatic EGFR-mutant NSCLC, compared to osimertinib alone or osimertinib combined with platinum-based chemotherapy
Timeline
- Start
- 2026-09-08
- Primary completion
- 2031-12-30
- Completion
- 2031-12-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Carboplatin | Small molecule | — | — |
| Comparator | Cisplatin | Other / unclassified | — | — |
| Subject | Iza-bren | Unknown | — | — |
| Subject | Osimertinib | Small molecule | — | — |
| Comparator | Pemetrexed | Small molecule | — | — |